The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2025 | Rare symptoms and complications in CLL
In this video, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly discusses the importance of being aware of potential rare symptoms and complications in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as these may often go unnoticed by physicians. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we talk a lot about some of the common presentations of CLL and SLL. Of course, we talk a lot about the treatment options and what we consider the more common way of treating CLL, the expected side effects, namely infections and cytopenias, and things like that. But I think in practice, we all encounter cases that are less common, but really at the same time are important to think about them...
So we talk a lot about some of the common presentations of CLL and SLL. Of course, we talk a lot about the treatment options and what we consider the more common way of treating CLL, the expected side effects, namely infections and cytopenias, and things like that. But I think in practice, we all encounter cases that are less common, but really at the same time are important to think about them. In practice, we all understand that once you get used to seeing the more common issues, you sometimes let your focus be on the more common problems and may potentially miss some of the important but rare presentations or complications. We have this session that we will talk about some of the less common presentations or complications. And for example, I’ll be discussing an interesting case of a patient with a CLL diagnosis who developed acquired von Willebrand syndrome that was successfully treated. I think it gives some awareness about thinking about some of these rare complications and also sharing our experience in terms of what treatments may be more effective.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting, advisory boards, steering committees, or data safety monitoring committees: AbbVie, Genentech, AstraZeneca, Genmab, Janssen, BeiGene/BeOne Medicines, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, Merck, Pfizer, Pierre Fabre; Research funding: Mustang Bio, Genentech, AbbVie, Beigene/BeOne Medicines, Astra-Zeneca, Genmab, Morphosys/Incyte, Vincerx; Stock options: Koi Biotherapeutics; Employment (spouse): Bristol Myers Squibb
